|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ANZCTR |
|
Last refreshed on:
|
11 June 2018 |
|
Main ID: |
ACTRN12618000922279 |
|
Date of registration:
|
31/05/2018 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Tocilizumab for the treatment of retroperitoneal fibrosis
|
|
Scientific title:
|
Tocilizumab treatment for induction of remission in patients with idiopathic retroperitoneal fibrosis (TOCIRET) |
|
Date of first enrolment:
|
10/07/2018 |
|
Target sample size:
|
18 |
|
Recruitment status: |
Not yet recruiting |
|
URL:
|
http://www.anzctr.org.au/ACTRN12618000922279.aspx |
|
Study type:
|
Interventional |
|
Study design:
|
Non-randomised trial
Single group |
|
Phase:
|
Phase 2
|
|
|
Key inclusion & exclusion criteria
|
|
Health Condition(s) or Problem(s) studied
|
|
retroperitoneal fibrosis
|
|
Intervention(s)
|
|
Treatment with the monoclonal antibody Tocilizumab, given intravenously at a dose of 8 mk/kg every month for 6 consecutive months. This therapeutic regimen will apply to all enrolled patients. The drug will be administered in a hospital setting (day hospital), which will allow evaluation of patient's adherence.
|
|
Source(s) of Monetary Support
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|